Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cinclus Pharma Holding AB ( (SE:CINPHA) ) has provided an announcement.
Cinclus Pharma Holding AB has announced the appointment of its Nomination Committee for the 2026 Annual General Meeting, consisting of members appointed by the company’s largest shareholders and the Chairman of the Board. This committee will propose resolutions for the meeting, including the election of the Chairman, board composition, and auditors’ fees, which could impact the company’s governance and strategic direction.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing drugs for acid-related diseases and disorders of the upper gastrointestinal tract. Their leading drug candidate, linaprazan glurate, aims to treat gastroesophageal reflux disease (GERD) more effectively than current treatments. The company is addressing a significant need for new drugs to treat severe cases of GERD, affecting millions in the US and EU.
Average Trading Volume: 66,100
Technical Sentiment Signal: Hold
Current Market Cap: SEK819.1M
Find detailed analytics on CINPHA stock on TipRanks’ Stock Analysis page.